Entry Point Capital, LLC Ultragenyx Pharmaceutical Inc. Transaction History
Entry Point Capital, LLC
- $188 Million
- Q2 2025
A detailed history of Entry Point Capital, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 10,575 shares of RARE stock, worth $297,263. This represents 0.2% of its overall portfolio holdings.
Number of Shares
10,575
Previous 10,982
3.71%
Holding current value
$297,263
Previous $397,000
3.27%
% of portfolio
0.2%
Previous 0.19%
Shares
5 transactions
Others Institutions Holding RARE
# of Institutions
330Shares Held
89.3MCall Options Held
1.05MPut Options Held
1.01M-
Vanguard Group Inc Valley Forge, PA10.2MShares$287 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$158 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.16MShares$117 Million0.55% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.22MShares$90.5 Million0.01% of portfolio
-
State Street Corp Boston, MA2.62MShares$73.6 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $1.97B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...